Mary Cunningham, MD
Gynecologic Oncology · Syracuse, NYNPI 1902902760
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $652 of the $814 with a category attached, or 80.0%. 10 manufacturers reported payments, led by Merck at 27.1% of the total. Reporting peaked in 2019 at $474 and has fallen 80.8% since, to $91 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in NY, where the typical reported total is $904.
Across 24 payments — averaging $33.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$221
- Clovis Oncology, Inc.$130
- GSK$124
- Amgen$111
- Lupin Inc.$102
- AstraZeneca$50
- plus $76 from 4 others
Across 30 payments — averaging $10,924 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$309K
- Merck$17K
- Clovis Oncology, Inc.$896
What the payments were for
- Food & beverage$65280%
- Education$16220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $221 |
| Clovis Oncology, Inc. | 4 | $130 |
| GSK | 1 | $124 |
| Amgen | 4 | $111 |
| Lupin Inc. | 1 | $102 |
| AstraZeneca | 3 | $50 |
| International Rehabilitative Sciences, Inc | 1 | $28 |
| Tesaro, Inc. | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $17 |
| Covidien LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$814 in reported general payments places this provider in the 45th percentile of 154 gynecologic oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 14 | $178 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Syracuse
- Wiley BunnSyracuse$201K
- Heidi GodoyAlbany$1.1M
- Bhavana PothuriNew York$366K
- Joyce BarlinAlbany$208K
- Ghadir SalameBrooklyn$179K
- Richard MooreRochester$124K
- Mario LeitaoNew York$116K
- Konstantin ZakashanskyNew York$93K
- Evelyn CantilloNew York$79K
- Farr NezhatNew York$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.